Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up
BioCentury This Week
00:00
Investing in a Company That Doesn't Show Monotherapy Eficacy
The point that i found interesting was what you said around relatin map not really showing a lot of monotherapy efficacy. I think the montre's been changing over the earth sance. We've been speaking with people, when when the ido blow up first happened, everyone is saying, don't invest in something that doesn't have mino therape activity.
Transcript
Play full episode
